Abstract
Brugada syndrome (BrS) is a genetic heart disease that predisposes individuals to ventricular arrhythmias and sudden cardiac death. Although implantable cardioverter-defibrillators (ICDs) and quinidine are primary treatments, recurrent BrS-triggered ventricular arrhythmias can persist. In this setting, epicardial substrate ablation has emerged as a promising alternative for symptomatic patients. Evaluate the effectiveness and safety of epicardial substrate ablation in patients with BrS. In this single-arm meta-analysis, we systematically searched PubMed, Embase, and Cochrane databases following PRISMA guidelines for studies including BrS patients with epicardial substrate ablation. Data was extracted, and statistical analysis was performed using random-effects modeling for proportional meta-analysis. 13 cohort studies comprising 555 BrS patients were included. The mean age at enrollment was 42.6 ± 12.3 years; 82.7% were males, and 50% exhibited spontaneous type 1 Brugada ECG pattern. Pooled analysis demonstrated resolution of the type 1 pattern in 91% of the cases (95% CI 80-98%; I2=86%) and elimination of abnormal electrograms in 91% (95% CI 78-99%; I2=74%). Rates of recurrent VT/VF and appropriate ICD therapies during post-ablation follow-up were 12% (95% CI 4-21%; I2=86%) and 8% (95% CI 2-18%; I2=87%), respectively. Epicardial substrate ablation shows promise for BrS patients experiencing BrS-triggered ventricular arrhythmias, offering therapeutic efficacy with an acceptable safety profile. High heterogeneity among studies highlights the need for further research and standardized protocols.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call